![]() ![]() Ilan Daskal, Bio-Rad's CFO, reiterated that the firm is seeing "a strong order backlog for ddPCR instruments" as it continues to work through the supply chain challenges but added that ddPCR consumables "continue to post strong double-digit growth." In a follow-up email, May noted that Bio-Rad is enacting an intentionally staged product launch for the QX600, making the parts constraint less of an issue and "not in and of itself rate limiting in our minds." That said, "We're very happy with the launch of the QX600 and the initial pipeline that we're building," May added. Simon May, executive VP of the life science business at Bio-Rad, said that the supply chain challenge was felt by the ddPCR business "a little more prominently than some of the other product lines." ![]() "As our backlog unwinds, we do expect to capture more of what we've put into our price increases," Last said.īio-Rad launched a six-color ddPCR instrument in the quarter called the QX600. "As the year progressed, has built and we've built inventory," said Last, adding that this is "reflective of our demand waiting on those final components, which procurement is spending a lot of time on chasing."Įxecutives noted that customers are waiting up to several months for orders, and that the firm is seeing elevated logistics costs as it express ships finished products when they are ready.īio-Rad is also currently offsetting inflation and other headwinds through pricing increases, but this does not apply to prior orders. However, the Hercules, California-based firm continues to experience a significant order backlog due to the supply of electronic components limiting instrument production. Overall, Bio-Rad is seeing its business shifting "back to normal" from the pandemic, Chief Operating Officer Andrew Last said. On a call to discuss third quarter results after the close of the market on Thursday, company executives said this has led to a significant order backlog that the firm sees resolving in the coming quarters.īio-Rad also addressed rumors about a potential merger on the call by noting that the firm's objectives for capital deployment include finding the best fit. NEW YORK – Supply chain challenges continue to impact Bio-Rad Laboratories' ability to deliver instruments. This story has been updated to include additional comments from Bio-Rad Laboratories about the QX600 product launch.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |